CryoPort, Inc. (NASDAQ:CYRX) Given Average Rating of “Moderate Buy” by Analysts

CryoPort, Inc. (NASDAQ:CYRX) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $16.3750.

Several research firms recently commented on CYRX. Needham & Company LLC upped their price target on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. BTIG Research increased their price objective on CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a report on Friday, July 24th. Weiss Ratings raised shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. KeyCorp raised their target price on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Finally, Guggenheim lifted their price target on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th.

Insiders Place Their Bets

In related news, Director Ramkumar Mandalam sold 23,214 shares of CryoPort stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $15.44, for a total transaction of $358,424.16. Following the transaction, the director owned 67,894 shares of the company’s stock, valued at $1,048,283.36. The trade was a 25.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Edward J. Zecchini sold 33,600 shares of CryoPort stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total transaction of $486,192.00. Following the transaction, the insider directly owned 109,719 shares in the company, valued at $1,587,633.93. This represents a 23.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 227,641 shares of company stock worth $3,622,515. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On CryoPort

Institutional investors have recently modified their holdings of the business. Basepoint Wealth LLC purchased a new stake in CryoPort during the fourth quarter worth about $34,000. Tower Research Capital LLC TRC boosted its holdings in shares of CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares during the period. Creative Planning purchased a new position in CryoPort during the 2nd quarter valued at about $96,000. Quadrature Capital Ltd bought a new stake in CryoPort during the 4th quarter worth approximately $97,000. Finally, State of Wyoming increased its holdings in shares of CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after purchasing an additional 3,301 shares during the period. 92.90% of the stock is owned by institutional investors.

CryoPort Stock Performance

Shares of NASDAQ CYRX opened at $15.33 on Friday. The stock has a 50 day moving average price of $15.41 and a 200 day moving average price of $11.75. CryoPort has a 52 week low of $6.69 and a 52 week high of $16.89. The stock has a market capitalization of $772.63 million, a PE ratio of 11.36 and a beta of 1.88.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The firm had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million. As a group, research analysts forecast that CryoPort will post -0.85 EPS for the current year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.